1. A pharmaceutical composition comprising glycopyrrolate in combination with a beta agonist selected from indacaterol, formoterol, vilanterol, carmoterol, olodaterol, optionally one or more pharmaceutically acceptable excipients. The pharmaceutical composition of claim 1, wherein the beta agonist is indacaterol. The pharmaceutical composition according to claim 2 or 3, in which indacaterol is in an amount ranging from 25 to 800 μg. The pharmaceutical composition of claim 1, wherein the beta agonist is formoterol. The pharmaceutical composition according to claim 4, in which formoterol is in an amount ranging from 12 to 24 μg. The pharmaceutical composition of claim 1, wherein the beta agonist is vilanterol. The pharmaceutical composition according to claim 6, in which vilanterol is in an amount ranging from 3 to 50 μg. The pharmaceutical composition of claim 1, wherein the beta agonist is carmoterol. The pharmaceutical composition of claim 8, wherein carmoterol is in an amount ranging from 1 to 4 μg. The pharmaceutical composition of claim 8 or 9, wherein carmoterol is in the form of carmoterol hydrochloride. The pharmaceutical composition according to claim 1, wherein the beta agonist is olodaterol. The pharmaceutical composition of claim 11, wherein olodaterol is in an amount ranging from 3 to 50 μg. The pharmaceutical composition of claim 1, comprising glycopyrrolate and vilanterol. The pharmaceutical composition according to claim 1, comprising glycopyrrolate and carmoterol. The pharmaceutical composition according to claim 1, comprising glycopyrrolate and olodaterol. Pharmaceutical composition containing glycopyr in combination1. Фармацевтическая композиция, содержащая гликопирролат в комбинации с бета-агонистом, выбранным из индакатерола, формотерола, вилантерола, кармотерола, олодатерола, необязательно одним или более фармацевтически приемлемыми эксципиентами.2. Фармацевтическая композиция по п.1, в которой бета-агонист представляет собой индакатерол.3. Фарм
